Enterprise record

Taysha Gene Therapies, Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:fa10748c-f43b-4192-a33a-dfa6208f0e21Version: public-1As of: unavailable

16 published Claims3 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 28, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 28, 2026

    Supports 3 claims
    • Legal Name: Taysha Gene Therapies, Inc. · Claim reviewed: Sep 28, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 28, 2026
    • Published Fact: US · Claim reviewed: Sep 28, 2026

  2. SEC DEF 14A 0001193125-26-168525

    sec def 14a · Source published: Apr 22, 2026 · Retrieved: Sep 13, 2026

    Supports 8 claims
    • Leadership Role: Sean P. Nolan: Chairman of the Board and Chief Executive Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Alison Long, M.D., Ph.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Laura Sepp-Lorenzino, Ph.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Phillip B. Donenberg, CPA: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Sukumar Nagendran, M.D.: President, Head of Research and Development and Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Kamran Alam: Chief Financial Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Sean P. Nolan: Chief Executive Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Sukumar Nagendran, M.D.: President and Head of Research and Development · Claim reviewed: Sep 28, 2026

  3. DEF 14A d94391ddef14a.htm

    sec proxy · Source published: Apr 22, 2026 · Retrieved: Sep 2, 2026

    Supports 5 claims
    • Leadership Role: Alison Long: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Laura Sepp-Lorenzino: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Phillip B. Donenberg: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Sean Stalfort: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Sukumar Nagendran: Director · Claim reviewed: Sep 28, 2026